Laura P. Hurley
Laura P. Hurley has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
Allison Kempe
Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, USA
15 shared publicationsLori A. Crane
Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
14 shared publicationsBrenda L. Beaty
Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, USA
13 shared publicationsMichaela Brtnikova
Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children’s Hospital Colorado, Aurora, USA
11 shared publicationsMegan C. Lindley
National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, USA
9 shared publicationsMandy A. Allison
Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, Colorado; Department of Pediatrics Children's Hospital Colorado, Aurora, Colorado
7 shared publications
Latest Publications
- Open Access
- 7 June 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2681305
Retrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021–23
Vaccine-associated enhanced disease (VAED) was recognized as a theoretical risk when COVID-19 vaccines were authorized. Epidemiologic data can identify a signal for VAED if vaccine effectiveness (VE) is negative for preventing serious illness. In 2021, we initiated a cohort study to examine VAED indirectly by estimating VE against COVID-19 hospitalization and severe illness in the Vaccine Safety Datalink. The study cohort included VSD enrollees who were age-eligible to receive mRNA COVID-19 vaccine from February 2021-March 2023. Outcomes were initial COVID-19-associated hospital admission and severe in-hospital complications (acute respiratory distress or failure). VE was estimated by dose, variant period, and for early (14–119 d) and late (≥120 d) post-vaccination periods. VE was defined as 100*(1- adjusted hazard ratio). Relative VE (rVE) was estimated for bivalent vaccine versus ≥2 monovalent vaccine doses. The hospitalization analysis included all 16,027 enrollees with COVID-19 hospitalization and a 5% random sample of non-hospitalized enrollees who contributed person-time (n = 138,238). Two-dose original monovalent VE against hospitalization exceeded 90% in most age groups during the pre-Delta and Delta periods. VE was lower during the Omicron period. During the Omicron BA.2/BA.4/BA.5/XBB period, a fourth monovalent dose or bivalent dose generated VE of 59%–78% across age groups with modest waning. rVE was 48%–60% across age groups for bivalent vaccine vs. ≥2 original monovalent doses. Overall, the results were similar for VE against severe in-hospital complication. In conclusion, there was no signal for VAED during any variant period or for any specific dose of monovalent or bivalent vaccine.
- 7 June 2026
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 22 (1) , 2681305
Open AccessRetrospective cohort study of mRNA COVID-19 vaccine-associated enhanced disease in the Vaccine Safety Datalink, 2021–23
Vaccine-associated enhanced disease (VAED) was recognized as a theoretical risk when COVID-19 vaccines were authorized. Epidemiologic data can identify a signal for VAED if vaccine effectiveness (VE) is negative for preventing serious illness. In 2021, we initiated a cohort study to examine VAED indirectly by estimating VE against COVID-19 hospitalization and severe illness in the Vaccine Safety Datalink. The study cohort included VSD enrollees who were age-eligible to receive mRNA COVID-19 vaccine from February 2021-March 2023. Outcomes were initial COVID-19-associated hospital admission and severe in-hospital complications (acute respiratory distress or failure). VE was estimated by dose, variant period, and for early (14–119 d) and late (≥120 d) post-vaccination periods. VE was defined as 100*(1- adjusted hazard ratio). Relative VE (rVE) was estimated for bivalent vaccine versus ≥2 monovalent vaccine doses. The hospitalization analysis included all 16,027 enrollees with COVID-19 hospitalization and a 5% random sample of non-hospitalized enrollees who contributed person-time (n = 138,238). Two-dose original monovalent VE against hospitalization exceeded 90% in most age groups during the pre-Delta and Delta periods. VE was lower during the Omicron period. During the Omicron BA.2/BA.4/BA.5/XBB period, a fourth monovalent dose or bivalent dose generated VE of 59%–78% across age groups with modest waning. rVE was 48%–60% across age groups for bivalent vaccine vs. ≥2 original monovalent doses. Overall, the results were similar for VE against severe in-hospital complication. In conclusion, there was no signal for VAED during any variant period or for any specific dose of monovalent or bivalent vaccine.
- Open Access
- 3 April 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2467548
Attitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023
COVID-19 vaccination rates are decreasing despite vaccination being the most effective tool against severe disease from COVID-19. From October 1, 2022, to February 1, 2023, we conducted a cross-sectional study among adults in the Vaccine Safety Datalink about attitudes and beliefs regarding bivalent COVID-19 Omicron booster vaccine (hereafter referred to as COVID-19 bivalent vaccine) stratifying by vaccination status and race and ethnicity. Analysis was weighted for response and selection bias. The response rate was 27% (385/1430); 33% [95% CI: 21%–44%] of respondents were ‘fully vaccinated’ (had received COVID-19 bivalent vaccine), 54% [42%−67%] were partially vaccinated, and 13% [7%−19%] were unvaccinated. Fully vaccinated adults were more likely to consider COVID-19 bivalent vaccine ‘very effective’ (64%, [43%−86%]) at preventing hospitalization due to COVID-19 than partially (31%, [12%−50%]) or unvaccinated (2%, [0%−6%]) adults. Fully vaccinated adults were more likely to report COVID-19 bivalent vaccine was ‘very safe’ (83%, [69%−98%]) than partially (43%, [23%−63%]) or unvaccinated adults (2%, 0%−6%). Non-Hispanic White adults were more likely to report COVID-19 bivalent vaccine was ‘very safe’ (71%, [54%−87%]) than Non-Hispanic Black (36%, [21%−50%]) and Hispanic (26%, [7%−45%]) adults. A dose–response effect between vaccination status and perceptions of COVID-19 bivalent vaccine safety and effectiveness was observed, with fully vaccinated respondents having the most favorable attitudes. Racial and ethnic differences in perceived vaccine safety were also found. Improved communication about vaccine effectiveness and safety is key to improving low vaccination rates.
- 3 April 2025
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2467548
Open AccessAttitudes and beliefs regarding COVID-19 and COVID-19 Omicron booster vaccine among adults in the vaccine safety datalink, 2022–2023
COVID-19 vaccination rates are decreasing despite vaccination being the most effective tool against severe disease from COVID-19. From October 1, 2022, to February 1, 2023, we conducted a cross-sectional study among adults in the Vaccine Safety Datalink about attitudes and beliefs regarding bivalent COVID-19 Omicron booster vaccine (hereafter referred to as COVID-19 bivalent vaccine) stratifying by vaccination status and race and ethnicity. Analysis was weighted for response and selection bias. The response rate was 27% (385/1430); 33% [95% CI: 21%–44%] of respondents were ‘fully vaccinated’ (had received COVID-19 bivalent vaccine), 54% [42%−67%] were partially vaccinated, and 13% [7%−19%] were unvaccinated. Fully vaccinated adults were more likely to consider COVID-19 bivalent vaccine ‘very effective’ (64%, [43%−86%]) at preventing hospitalization due to COVID-19 than partially (31%, [12%−50%]) or unvaccinated (2%, [0%−6%]) adults. Fully vaccinated adults were more likely to report COVID-19 bivalent vaccine was ‘very safe’ (83%, [69%−98%]) than partially (43%, [23%−63%]) or unvaccinated adults (2%, 0%−6%). Non-Hispanic White adults were more likely to report COVID-19 bivalent vaccine was ‘very safe’ (71%, [54%−87%]) than Non-Hispanic Black (36%, [21%−50%]) and Hispanic (26%, [7%−45%]) adults. A dose–response effect between vaccination status and perceptions of COVID-19 bivalent vaccine safety and effectiveness was observed, with fully vaccinated respondents having the most favorable attitudes. Racial and ethnic differences in perceived vaccine safety were also found. Improved communication about vaccine effectiveness and safety is key to improving low vaccination rates.
- Open Access
- 27 March 2025
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 24 (1) , 230-241
Strengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States
Non-survey-based data sources (e.g. electronic health records, administrative claims) have been used to estimate vaccination coverage among US adults. However, these data sources were not collected for research or surveillance purposes and may have substantial limitations. The objectives of this narrative review were to: 1) identify published studies that used non-survey-based data sources to estimate adult vaccination coverage for one or more routinely recommended vaccines; and 2) summarize the strengths and limitations of these data sources for coverage assessments. Thirty-four publications derived from 9 data sources were reviewed: 16 publications were in a general population (i.e. defined by age), 12 were among pregnant women, and 6 were among individuals with chronic health conditions. While several data sources used continuous health insurance enrollment to define the study population, doing so limited generalizability to stably insured populations. Methods for obtaining race and ethnicity data were complex and potentially subject to bias. None of the reviewed studies presented any formal assessment of vaccine data validity. While multiple non-survey-based data sources have been used to assess adult vaccination coverage in the United States, important limitations exist, including related to generalizability, data validity, and risk of bias.
- 27 March 2025
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 24 (1) , 230-241
Open AccessStrengths and limitations of non-survey-based data sources for assessing adult vaccination coverage in the United States
Non-survey-based data sources (e.g. electronic health records, administrative claims) have been used to estimate vaccination coverage among US adults. However, these data sources were not collected for research or surveillance purposes and may have substantial limitations. The objectives of this narrative review were to: 1) identify published studies that used non-survey-based data sources to estimate adult vaccination coverage for one or more routinely recommended vaccines; and 2) summarize the strengths and limitations of these data sources for coverage assessments. Thirty-four publications derived from 9 data sources were reviewed: 16 publications were in a general population (i.e. defined by age), 12 were among pregnant women, and 6 were among individuals with chronic health conditions. While several data sources used continuous health insurance enrollment to define the study population, doing so limited generalizability to stably insured populations. Methods for obtaining race and ethnicity data were complex and potentially subject to bias. None of the reviewed studies presented any formal assessment of vaccine data validity. While multiple non-survey-based data sources have been used to assess adult vaccination coverage in the United States, important limitations exist, including related to generalizability, data validity, and risk of bias.
- 6 July 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (4) , 986-993
Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine
Background Herpes zoster vaccination rates remain low despite longstanding national recommendations to vaccinate immunocompetent adults aged ≥ 50 years. The Advisory Committee on Immunization Practice (ACIP) updated its recommendations for recombinant zoster vaccine (RZV) in October 2021 to include immunocompromised adults aged ≥19 years. Objective To assess practices, attitudes, and knowledge about RZV, barriers to recommending RZV, and likelihood of recommending RZV to patients with various immunocompromising conditions. Design Mail and internet-based survey conducted from May through July 2020. Participants General internists and family physicians throughout the USA. Main Measures Survey responses. Key Results The response rate was 66% (632/955). Many physicians were already recommending RZV to immunocompromised populations, including adults ≥50 years with HIV (67% of respondents) and on recombinant human immune modulator therapy (56%). Forty-seven percent of respondents both stocked/administered RZV and referred patients elsewhere, frequently a pharmacy, for vaccination; 42% did not stock RZV and only referred patients. The majority agreed pharmacies do not inform them when RZV has been given (64%). Physicians were generally knowledgeable about RZV; however, 25% incorrectly thought experiencing side effects from the first dose of RZV that interfere with normal activities was a reason to not receive the second dose. The top reported barrier to recommending RZV was experience with patients declining RZV due to cost concerns (67%). Most physicians reported they would be likely to recommend RZV to immunocompromised patients. Conclusion Most primary care physicians welcome updated ACIP RZV recommendations for immunocompromised adults. Knowledge gaps, communication issues, and financial barriers need to be addressed to optimize vaccination delivery.
- 6 July 2022
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 38 (4) , 986-993
Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine
Background Herpes zoster vaccination rates remain low despite longstanding national recommendations to vaccinate immunocompetent adults aged ≥ 50 years. The Advisory Committee on Immunization Practice (ACIP) updated its recommendations for recombinant zoster vaccine (RZV) in October 2021 to include immunocompromised adults aged ≥19 years. Objective To assess practices, attitudes, and knowledge about RZV, barriers to recommending RZV, and likelihood of recommending RZV to patients with various immunocompromising conditions. Design Mail and internet-based survey conducted from May through July 2020. Participants General internists and family physicians throughout the USA. Main Measures Survey responses. Key Results The response rate was 66% (632/955). Many physicians were already recommending RZV to immunocompromised populations, including adults ≥50 years with HIV (67% of respondents) and on recombinant human immune modulator therapy (56%). Forty-seven percent of respondents both stocked/administered RZV and referred patients elsewhere, frequently a pharmacy, for vaccination; 42% did not stock RZV and only referred patients. The majority agreed pharmacies do not inform them when RZV has been given (64%). Physicians were generally knowledgeable about RZV; however, 25% incorrectly thought experiencing side effects from the first dose of RZV that interfere with normal activities was a reason to not receive the second dose. The top reported barrier to recommending RZV was experience with patients declining RZV due to cost concerns (67%). Most physicians reported they would be likely to recommend RZV to immunocompromised patients. Conclusion Most primary care physicians welcome updated ACIP RZV recommendations for immunocompromised adults. Knowledge gaps, communication issues, and financial barriers need to be addressed to optimize vaccination delivery.
- 28 October 2021
- Published by Elsevier in Academic Pediatrics
- Vol. 22 (4) , 559-563
US Primary Care Providers’ Experiences and Practices Related to Routine Pediatric Vaccination During the COVID-19 Pandemic
- 28 October 2021
- Published by Elsevier in Academic Pediatrics
- Vol. 22 (4) , 559-563
US Primary Care Providers’ Experiences and Practices Related to Routine Pediatric Vaccination During the COVID-19 Pandemic
- 14 May 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (9) , 2612-2618
Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years
Background: In June 2019, the Advisory Committee on Immunization Practices recommended discontinuing the routine use of the pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years and instead recommended PCV13 be used based on shared clinical decision making (SCDM). Objectives: We wanted to assess among primary care physicians (1) knowledge and attitudes regarding the new SCDM PCV13 recommendation and (2) how the new recommendation will affect their likelihood of recommending PCV13 to adults aged ≥65 years. Design: This was done by mail and internet‐based survey, which was conducted October 2019 through January 2020. The study was carried out on a nationally representative sample of general internists (GIMs) and family physicians (FPs). Results: The response rate was 64% (617/968, GIM 57%, FP 71%). Only 41% of respondents were aware of the SCDM PCV13 recommendation in adults aged ≥65 years; 76% agreed (37% “Strongly,” 39% “Somewhat”) that their patients aged ≥65 years will get confused by having a SCDM recommendation for PCV13 and a routine recommendation for the pneumococcal polysaccharide vaccine (PPSV23); 60% agreed (18% “Strongly,” 42% “Somewhat”) that they were unsure of what points to emphasize when having a SCDM conversation with an adult aged ≥65 years about receiving PCV13. Just over 50% reported they would be less likely to recommend PCV13 for adults aged ≥65 years as a result of the new recommendation, but 42% reported that their recommendation for PCV13 would not change. Conclusions: Word of the new ACIP recommendation for PCV13 for adults aged ≥65 years needs to be further disseminated. Investigation into why some physicians do not plan to change their recommendations is warranted.
- 14 May 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 69 (9) , 2612-2618
Physician survey regarding updated PCV13 vaccine recommendations for adults ≥65 years
Background: In June 2019, the Advisory Committee on Immunization Practices recommended discontinuing the routine use of the pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years and instead recommended PCV13 be used based on shared clinical decision making (SCDM). Objectives: We wanted to assess among primary care physicians (1) knowledge and attitudes regarding the new SCDM PCV13 recommendation and (2) how the new recommendation will affect their likelihood of recommending PCV13 to adults aged ≥65 years. Design: This was done by mail and internet‐based survey, which was conducted October 2019 through January 2020. The study was carried out on a nationally representative sample of general internists (GIMs) and family physicians (FPs). Results: The response rate was 64% (617/968, GIM 57%, FP 71%). Only 41% of respondents were aware of the SCDM PCV13 recommendation in adults aged ≥65 years; 76% agreed (37% “Strongly,” 39% “Somewhat”) that their patients aged ≥65 years will get confused by having a SCDM recommendation for PCV13 and a routine recommendation for the pneumococcal polysaccharide vaccine (PPSV23); 60% agreed (18% “Strongly,” 42% “Somewhat”) that they were unsure of what points to emphasize when having a SCDM conversation with an adult aged ≥65 years about receiving PCV13. Just over 50% reported they would be less likely to recommend PCV13 for adults aged ≥65 years as a result of the new recommendation, but 42% reported that their recommendation for PCV13 would not change. Conclusions: Word of the new ACIP recommendation for PCV13 for adults aged ≥65 years needs to be further disseminated. Investigation into why some physicians do not plan to change their recommendations is warranted.
- Open Access
- 1 March 2021
- Published by Elsevier in Preventive Medicine Reports
- Vol. 21, 101296
The potential for centralized reminder/recall to increase immunization rates: A national survey of immunization information systems (IIS) managers
- 1 March 2021
- Published by Elsevier in Preventive Medicine Reports
- Vol. 21, 101296
Open AccessThe potential for centralized reminder/recall to increase immunization rates: A national survey of immunization information systems (IIS) managers